title: Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors.
abstract: Iodine-131 3F8, a murine IgG3 monoclonal antibody that targets to GD2-bearing tumors, was administered intravenously to 12 patients with brain tumors. Six patients received 2 mCi (0.74 Bq) of 131I-3F8, five patients 10 mCi (3.7 Bq)/1.73 m2 of 131I-3F8, and one patient 2.6 mCi (0.96 Bq) of 124I-3F8, with no side-effects. Nine of 11 malignant gliomas and the single metastatic melanoma showed antibody localization, with the best tumor delineation on single-photon emission tomography (SPET) following 10 mCi (3.7 Bq)/1.73 m2 dose. No nonspecific uptake in the normal craniospinal axis was detected. There was no difference in the pharmacokinetics of low-dose versus the higher-dose antibody groups; plasma and total-body half-lives were 18 h and 49 h, respectively. Surgical sampling and time-activity curves based on quantitative imaging showed peak uptake in high-grade glioma at 39 h, with a half-life of 62 h. Tumor uptake at time of surgery averaged 3.5 x 10(-3) %ID/g and peak activity by the conjugate view method averaged 9.2 x 10(-3) %ID/g (3.5-17.8). Mean radiation absorption dose was 3.9 rad per mCi injected (range 0.7-9.6) or 10.5 cGy/Bq (range 1.9-26). There was agreement on positive sites when immunoscintigraphy was compared with technetium-99m glucoheptonate/diethylene triamine penta-acetic acid planar imaging, thallium-201 SPET, and fluorine-18 fluorodeoxyglucose positron emission tomography. Taken together, these data suggest that quantitative estimates of antibody targeting to intracranial tumors can be made using the modified conjugate view method.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA.
authors.forename: E
authors.initials: E
authors.lastname: Arbit
authors.forename: N K
authors.initials: NK
authors.lastname: Cheung
authors.forename: S D
authors.initials: SD
authors.lastname: Yeh
authors.forename: F
authors.initials: F
authors.lastname: Daghighian
authors.forename: J J
authors.initials: JJ
authors.lastname: Zhang
authors.forename: C
authors.initials: C
authors.lastname: Cordon-Cardo
authors.forename: K
authors.initials: K
authors.lastname: Pentlow
authors.forename: A
authors.initials: A
authors.lastname: Canete
authors.forename: R
authors.initials: R
authors.lastname: Finn
authors.forename: S M
authors.initials: SM
authors.lastname: Larson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000000981:diagnostic imaging*; D002648:Child; D003847:Deoxyglucose / Q000031:analogs & derivatives; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D005909:Glioblastoma / Q000000981:diagnostic imaging*; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D015609:Organotechnetium Compounds; D016719:Radioimmunodetection; D013400:Sugar Acids; D016284:Technetium Tc 99m Pentetate; D013794:Thallium Radioisotopes; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D005462:Fluorine Radioisotopes; D007457:Iodine Radioisotopes; D015609:Organotechnetium Compounds; D013400:Sugar Acids; D013794:Thallium Radioisotopes; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose; C100014:technetium Tc 99m gluceptate; D016284:Technetium Tc 99m Pentetate